CM-101 in PSC Patients -The SPRING Study

The requested reference [87702c0c442157f91752a2d2aea18f51de4da4aa] no longer exists in our database. It has been replaced by the current reference: [9e495dab46c7013708c88b2723ea1098ed48fb74]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.
Epistemonikos ID: fd492597c80221f5c772c453f19083147091afb4
First added on: May 07, 2024